UNCOVERED: Biofrontera inc - The Untold Story

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch

Pelthos Therapeutics Inc. (NYSE:PTHS) on Friday acquired the U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. (NASDAQ:BFRI) and Ferrer Internacional S.A.

Benzinga · Nov 7, 2025

Peering Into Biofrontera Inc. - Common Stock's Recent Short Interest

Biofrontera Inc. - Common Stock's (NASDAQ:BFRI) short percent of float has risen 6.56% since its last report. The company recently reported that it has 821.90 thousand shares sold short, which is 15.93% of all regular shares that are available for trading.

Benzinga · Apr 14, 2022

Why Biofrontera Stock Is Surging Today

Biofrontera Inc (NASDAQ: BFRI) shares are trading significantly higher Wednesday after the company announced it received U.S. Food and Drug Administration approval for its cGMP laboratory in Germany.

Benzinga · Apr 13, 2022